• Tues news: Prostate cancer trials to watch. Merck’s subcutaneous Keytruda. Apellis sees positive in Astellas CRL. Future of Medicare price negotiations. JNJ psoriasis results. See more on our front page

Abhay, please respond.

















Are you stupid? We are already scheduling training sessions for the field sales group to get up to standard with the organization. Be trained. Be better Territory Managers.